ACSM2B

Across TCGA pan-cancer cohorts, ACSM2B mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ACSM2B data layer compared with 19 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ACSM2B mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ACSM2B expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC are the cancer types where ACSM2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	0.946	0.735	.005	55	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

ACSM2B–CCRCC (OS)

Open the CCRCC breakdown →